IART
Integra Lifesciences Holdings Corp Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$12.75Close
$1.2BMarket cap
$8.90 – $19.8552-week range
Jan 15, 2027Next report · estimated
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 29 · weaker than 71% of stocks over 12 months
- Far from its high 36% below its 52-week high
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
36%
1wk
up 7.1%
price change
1mo
down 21.7%
price change
12-month return
up 8%
market up 11% ·
its own down 28%
F-score
4 / 9
Weak
Altman Z
0.68
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.1×
price / book
Earnings yield
down 29.6%
EBIT / enterprise value
Cheaper than
36%
of the market · expensive
Revenue growth
up 2%
year on year
EPS growth
—
latest quarter
Sales growth
up 2%
latest quarter · +2 pts
ROE
down 40%
return on equity
Free cash margin
down 2%
-$31.1M FCF
D/E
0.70
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- issued more shares
- gross margin narrowed
- assets working less efficiently
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
Trade setup
ATR%
5.6%
$0.71 a day · 2×ATR $11.32
RS
29 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.15
50 sessions
Implied move
—
no scheduled report
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Gross margin narrowing Gross margin fell from 54.8% to 50.9%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 21, 2026
Last shock
Oct 2, 2026-21% in one session3.1× volumeon results+1% since
Financials
- Gross 51%
- Net -32%
- Free cash -2%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B |
| Gross margin | 62% | 61% | 62% | 57% | 55% | 51% |
| Operating income | $151.4M | $197.2M | $238.9M | $111.5M | $28.4M | -$493.4M |
| Net income | $133.9M | $169.1M | $180.6M | $67.7M | -$6.9M | -$516.8M |
| Net margin | 10% | 11% | 12% | 4% | -0% | -32% |
| Earnings per share | $1.57 | $1.98 | $2.16 | $0.84 | -$0.09 | -$6.74 |
| Free cash flow | $164.9M | $264.4M | $222.1M | $73.1M | $25.0M | -$31.1M |
| Free cash margin | 12% | 17% | 14% | 5% | 2% | -2% |
| Cash | $470.2M | $513.4M | $456.7M | $276.4M | $246.4M | $235.0M |
| Long-term debt | $877.5M | $843.8M | $775.0M | $775.0M | $760.5M | $726.6M |
| Shareholders' equity | $1.5B | $1.7B | $1.8B | $1.6B | $1.5B | $1.0B |
| Shares outstanding | 89.25m | 89.60m | 90.48m | 90.92m | 91.61m | 92.29m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 23, 2026 | Quarterly ↗ | Sep 30, 2026 | 23d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Jul 29, 2024 | Quarterly ↗ | Jun 30, 2024 | 29d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 21, 2026 | Results ↗ |
| Oct 19, 2026 | Material agreement · Agreement ended · New obligation · Regulation FD ↗ |
| Oct 9, 2026 | Regulation FD ↗ |
| Oct 2, 2026 | Results · Regulation FD ↗ |
| Sep 8, 2026 | Regulation FD ↗ |
| Jul 29, 2026 | Results ↗ |
| May 8, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Director or officer change ↗ |
| May 5, 2026 | Results ↗ |
| Apr 15, 2026 | Material agreement ↗ |
| Feb 26, 2026 | Results ↗ |
| Dec 12, 2025 | Director or officer change ↗ |